Anais Bodere

CHU Rennes
Rennes, FR 
Clinical Trials:Currently Recruiting for 1 Trial
CHU Rennes
Rennes, FR 

Overview

Anais Bodere practices practicing medicine in Rennes, France.

Her clinical expertise encompasses Anal Fissure, Bowel Incontinence, Colorectal Cancer, and Lung Metastases.

She is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 6 clinical trials.

Gender

Female

Locations

CHU Rennes
Rennes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Enrollment Status: Recruiting
Publish Date: July 09, 2025
Intervention Type: Drug
Study Drugs: Oxaliplatin intravenous, 5 Fu, Folinic Acid, Oxaliplatin intra-arterial, Panitumumab, Bevacizumab
Study Phase: Phase 3
Phase II Randomized Study Measuring the Interest of Pursuing or Not the CT for Non-progressive Patients With Metastatic Esophageal Squamous-cell Cancer After 6 Weeks of LV5FU2-paclitaxel Given After a 1st Line Fluoropyrimidine/Pt Salt CT
Phase II Randomized Study Measuring the Interest of Pursuing or Not the CT for Non-progressive Patients With Metastatic Esophageal Squamous-cell Cancer After 6 Weeks of LV5FU2-paclitaxel Given After a 1st Line Fluoropyrimidine/Pt Salt CT
Enrollment Status: Terminated
Publish Date: March 18, 2026
Intervention Type: Drug
Study Drug: Chemotherapy
Study Phase: Phase 2
Phase III Study to Evaluate the Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters.
Phase III Study to Evaluate the Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters.
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug
Study Phase: Phase 3
Multicenter Randomized Phase II Study Comparing the Effectiveness and Tolerance of Avelumab Versus Standard 2nd Line Treatment Chemotherapy in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (MSI)
Multicenter Randomized Phase II Study Comparing the Effectiveness and Tolerance of Avelumab Versus Standard 2nd Line Treatment Chemotherapy in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (MSI)
Enrollment Status: Completed
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drugs: FOLFOX Regimen, FOLFIRI Protocol, Avelumab, Panitumumab, Aflibercept
Study Phase: Phase 2
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: FOLFIRINOX, LV5FU2, FOLFIRI.3, Gemcitabine
Study Phase: Phase 2
Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers
Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

9 Total Publications

Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma.
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma.
Journal: Communications medicine
Published: July 22, 2024

Frequently Asked Questions about Anais Bodere

Is Anais Bodere a top-rated expert for Anal Fissure?

MediFind is an objective health platform that identifies experts based on real-world data. Anais Bodere is classified as an Experienced expert for Anal Fissure, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Anais Bodere participate in research or clinical trials?

Yes. Anais Bodere has published 9 articles and abstracts on conditions like Anal Fissure. You can view a list of Anais Bodere's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bodere's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile